For many men, the treatment of sexual dysfunctions such as premature ejaculation may well be most effective when pharmacotherapy is combined with psychotherapy. Yet the essential elements of psychotherapy that might best be combined with pharmacological-based therapy are currently unknown. Support for evidence-based studies that identify key components of psychotherapy that might improve positive long-term outcomes, including patient satisfaction, are needed. Pharmaceutical companies having a vested interest in achieving both treatment adherence and improved patient outcomes could benefit from such information.
A Historical Perspective
For decades, the most promising treatment for men with premature ejaculation (PE) utilized some variation of the stop-squeeze and stop-pause techniques introduced by Masters and Johnson 1 and Kaplan 2 respectively. Initial success rates were reportedly so promising -higher than 90% -that the need for publication of careful, ongoing replications seemed pointless given the robustness of the treatment effect. Additionally, because of the natural tension between therapeutic and research objectives, well-controlled studies -such as treatment vs matched-control tests -were never carried out, and only a handful of studies using self-as-control, waiting list, or even no-control studies were ever reported. 3 As a result, the accumulation of studies documenting the efficacy of behavioral strategies in the treatment of PE was meager.
Indeed, most research implemented during or shortly after the Masters and Johnson and the Kaplan breakthroughs focused on specific parameters and formats that influenced treatment success: the optimal number of treatment sessions, comparisons of group vs couple vs individual treatment formats, and so on. 4 For the most part, these studies used simple and/or single outcome measures, mainly patient or couple's sexual satisfaction, which although critically important to any efficacy study, were not sufficient to establish the effectiveness of the prescribed procedures on dimensions specific to ejaculatory latency and control. Furthermore, even though success rates reported in these later studies did not match those of earlier reports, researchers and clinicians seldom questioned -at least initially -the behavioral-based treatment procedures themselves. Eventually, however, the cumulative failure by others, both in practice and in research, to achieve similarly spectacular results brought new scrutiny to earlier studies. We now know in retrospect that the success rates reported by Masters and Johnson were influenced by their carefully selected clients -characterized by healthy relationships, without significant co-morbid physical or psychological disorders, with significant economic means and high personal motivation and with relatively high sexual naiveté (common during that era). 4 Despite the mismatch of success rates between the pioneering studies of Masters and Johnson and Kaplan and those of later parametric studies, clinical findings were nevertheless still promising, with short-term success rates typically reported at or above 70%. 5, 6 However, treatment effects assessed 1-3 years later in these patients proved less encouraging. On average, only about 60% of patients reported long-term satisfactory outcomes, with at least one study reporting results as low as 25%.
Given the diminishing returns over time, along with existing economic and social barriers for treatment, research on psychotherapeutic treatment strategies for PE essentially withered on the vine, the last significant clinical study having been carried out some 20 years ago. 8, 9 Yet over the past 20 years, psychotherapeutic techniques have undergone significant transformation and improvement. At the broader level, they have incorporated new cognitive approaches, refined factors key for selecting therapeutic strategies, and identified important distinctions between content, strategy and process. And specific to the treatment of men with PE, these improved methodologies have been combined with existing cognitive-behavioral techniques to provide, for many clinicians, an effective set of tools for the treatment of this sexual dysfunction. Despite this evolution in therapeutic techniques, however, few studies have attempted to systematically test the effectiveness and efficaciousness of contemporary cognitive-behavioral approaches in the treatment of PE using a controlled methodology. Even fewer have included detailed descriptions of the interventions necessary to judge the efficacy of the treatment procedures for PE -whether they were those originally advocated by Masters and Johnson or Kaplan or more recent renditions employing broader cognitive-behavioral strategies. 10 And no empirically based studies have specified which particular interventions contributed most to improving ejaculatory functioning. Finally, beyond effective content of the therapeutic process, investigations on the amelioration of PE have not examined key components considered essential to effective outcomes of therapy, namely assessment of the quality of the patient-provider collaboration and identification of outcome-mediating patient values and characteristics.
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The current environment It was against this backdrop that the ejaculatoryretarding effects of tricyclic and SSRI antidepressants first emerged in the 1970s as potential tools in the treatment of PE. Well-controlled studies conducted over the past decade with these agents have now radically changed the options available to health providers for the treatment of PE. 12 Indeed, such research has led to new postulations regarding possible neurobiological causes of PE. 13 Less appropriately, these biologically based studies have, in some instances, led to head-to-head comparisons of outcomes using pharmacological treatment with outcomes using cognitive-behavioral strategies. Such contests, however, are meaningless as they compare decades old data, procedures and outcome measures (in the case of cognitivebehavioral strategies) with recent studies utilizing newly developed/researched outcome measures investigated in placebo-controlled, crossover research designs (as is typical of recent pharmacological studies).
Yet as the trend shifts toward medical-based treatment for PE (although it is uncertain whether recent SSRIs under development will receive regulatory agency approval for the treatment of PE, new pharmacological treatments will undoubtedly emerge over the next decade), we would urge that now is the time for pharmaceutical companies to make significant investments in understanding the role of psychotherapy in the treatment of PE, especially when combined with medication treatment. We make this recommendation based on three rationales. First, we simply do not know how effective contemporary psychotherapeutic procedures might be in the treatment of PE; most published data are over 20 years old and represent different techniques than today's therapies. Nor do we understand the reasons why the effectiveness of behavioral procedures described by Masters and Johnson and by Kaplan diminished over timewhether the procedures themselves became less effective, whether the couples no longer bothered to use them, or whether the treatment population changed significantly. Second, we know that when used as the sole intervention, pharmacological treatments for PE have limited efficacy. They do not work for all patients. Equally significant, since current pharmacotherapy treatments offer only symptomatic relief (that is, they do not cure the problem), withdrawal of medication results in relapse, suggesting that long-term benefits are unlikely, or at the least, uncertain. Third, even for those that do find medications or other medical procedures effective, adherence may be under 50% (cf. PDE-5s in the treatment of erectile dysfunction). 14, 15 Medical treatments alone do not address complex interactions among patient expectations, adverse events, insurance coverage and costs and the myriad psychosocial factors likely to impact overall treatment satisfaction and adherence. 16 Given the pressures of today's cost containment managed care environment, physicians, sex therapists and other appropriately trained mental health service providers (for example, psychologists, counselors, and nurse practitioners) must provide both effective and efficacious therapy while simultaneously selecting treatments that are empirically validated or at least empirically supported. Furthermore, consensus is building that most medical approaches to the treatment of sexual dysfunction, if they are to be effective in the long run, must take into account an array of non-medical, individual and relationship factors. This assumption argues that combining pharmacotherapy with counseling is likely to augment the effectiveness and efficacy of an overall treatment protocol -indeed the combination of both approaches is likely to provide mutually enhancing synergies for most patients and their
Research on the efficacy of psychotherapy on premature ejaculation D Rowland et al partners. 10 Yet a fundamental question begs to be answered: which contents, strategies and processes of psychotherapy are most effective in helping men with PE, and which can be most effectively integrated with pharmacotherapy to enhance longterm treatment outcomes. Because research funds to carry out well-designed studies have been lacking, evidence-based support for cognitive-behavioral therapy (CBT) protocols and/or combined medical/ CBT protocols in the treatment of PE is virtually non-existent. As a result, the attractiveness of these approaches (relative to the more evidence-based pharmacological strategies) to patients, physicians and managed care providers is diminished, and patients and their partners are deprived of strategies and options that could potentially optimize treatment outcomes.
Reasons for pharmaceutical support of psychological intervention research
In this review, we are not advocating that pharmaceutical companies should support research on the treatment of PE through CBT and/or combined pharmacotherapy/CBT based on purely altruistic motives. Rather, we contend that pharmaceutical companies would serve their own best interests by supporting such research. The reasons, discussed below in greater detail, fall into four domains. Specifically, the support could (1) increase our understanding of which components of therapy content enhance treatment outcomes. (2) increase our understanding of how the comprehensive therapeutic process contributes to treatment success. (3) contribute to the development of emerging therapeutic paradigms and (4) provide a general 'good will' benefit to the pharmaceutical industry.
Increasing our understanding of which components of therapy content enhance treatment outcomes Our current knowledge of psychotherapeutic effects on PE is limited in scope and out dated. In general, however, psychotherapy involves both general strategies, and ones specific to the dysfunction or problem (in this case, PE). General strategies may address educational aspects of the problem, teach basic communication skills, manage expectations, help develop emotional control, reduce anxiety and so on. Specific strategies for PE may include certain types of cognitive training; schema confrontation and thought stopping; sensate focus and somatic awareness enhancement; and behavioral techniques such as pause-squeeze, specific intercourse positions and appropriate foreplay strategies. 17 For most patients with PE, some or all of the above strategies may be implemented in the course of sex therapy or with adjunctive counseling, depending on individual and relationship characteristics. Currently unknown is whether general vs PE-specific psychotherapeutic strategies are more effective, and whether specific strategies within each of these general vs PE-specific domains impart more benefit than others. At the very least, however, cogent arguments can be made for the inclusion of some form of psychological/behavioral intervention to help patients/couples make better use of medical therapies, to learn skills to delay ejaculation once off medication, to bolster sexual confidence and to enhance patient and partner sexual satisfaction. 18 Such arguments, however, currently lack empirical support.
Why is the above important to pharmaceutical companies? Pharmacological interventions, when applied alone, are likely to be less effective in the long-term treatment of sexual dysfunctions than combination therapies. However, before effective and efficient combination protocols can be implemented, a prioritizing of counseling strategies first needs to be established. Knowing, for example, that educating couples about the problem and facilitating sexual communication yields substantial improvement in the condition (a hypothetical statement at this point) offers important guidance regarding educational materials that should be provided and professional guidance that could be recommended for effective long-term treatment. Likewise, knowing that other procedures are less effective could obviate the need to incorporate those components into a combination protocol, except perhaps in the most difficult cases. Also knowing which PE-specific strategies have the greatest effect (for example, attending to premonitory sensations vs pause-squeeze) could help focus the therapy so that maximal benefit is achieved in the minimal number of sessions. Such informationcurrently unavailable due to a lack of evidencebased studies -could help prioritize those elements of therapy likely to have the greatest benefit for couples considering pharmacotherapy. Furthermore, incorporation of outcome measures beyond sexual satisfaction to include satisfaction both with the relationship in general and with the treatment process itself would enable a more comprehensive assessment of treatment effects. Specifically, such an assessment could better measure both medication and psychologic-behavioral intervention results. A focus on adherence to treatment and handling relapse would likely increase beneficial outcomes while also providing an important new subfocus for determining a key intermediary for long-term outcomes of treatment. In summary, then, relevant elements of therapy -those empirically supported as contributing the greatest gains to relationship and treatment satisfaction -could supplement pharmacotherapy to increase long-term treatment success.
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Why should the quality of the patient-provider relationship be of interest to pharmaceutical companies? Research on psychotherapy outcomes indicates that the bond between the patient and provider and their agreement on tasks and goals are critically important factors to overall treatment compliance and subsequent treatment success and satisfaction. 19 Such findings suggest a strategy for improving long-term adherence in the pharmacological treatment of PE. Although the physician's time is very limited, recent studies suggest that both quantity and quality of provider-patient communications enhance diagnosis and treatment compliance. 20 Alternatively, since most physicians have neither the time nor training to investigate issues of treatment tasks and goals with their patients -much less to establish deeper empathy with them -the opportunity to develop a trusting relationship with a collaborating therapist may offer an important means for ensuring positive long-term treatment outcomes. Understanding the role of such qualitative aspects of the patient-provider interactions -as well as who (therapist, nurse, physician) might be in the best position to establish this trusting relationship -would be particularly pertinent in the treatment of personally sensitive issues such as PE.
Separate from attention to the patient-provider relationship, a focus on patient characteristics should also be of interest to the pharmaceutical companies. Knowing such characteristics might assist in determining the best initial course of intervention: medication alone, psychotherapy alone, or combined therapy. Research shows, for example, that some men do not respond to pharmacotherapy, others do not tolerate the side effects well; men in both groups are candidates for attrition. Even among men who do benefit from the treatment, overall treatment satisfaction is often mitigated or enhanced by 'softer' psychological variablesexpectation, motivation, initial level of concern about the problem, and so on. In fact, such factors are as good predictors of treatment satisfaction as specific drug effects on ejaculatory latency. 21 Although segmenting populations based on patient characteristics may reduce the 'defined' treatment group, it is also likely to increase the effect size (and effectiveness) of the treatment and, as important, treatment satisfaction. For example, factors such as length of time the couple has been abstinent, quality of the relationship, motivation for resumed lovemaking, level of personal problems and psychopathology all contribute to the likelihood that couples will be able to resume a successful and satisfying sexual relationship. Depending on such factors, some couples will have no or insignificant barriers to the use of medications, other mild or moderate barriers, or still others profound psychological/interpersonal difficulties that significantly reduce the likelihood of successful use of medications. 16 In general, those with moderate or profound barriers to successful use of medication are likely to require more extensive psychotherapy delivered by more extensively trained sex therapists to achieve a substantial improvement in sexual satisfaction. Such segmentation as those proposed above would enable pharmaceutical companies to weigh more carefully the benefits of serving larger treatment populations with smaller effects against serving smaller treatment populations with larger effectsthe latter population being more likely to continue treatment over the long run.
Consistent with the idea above -that patient characteristics affect treatment outcomes -psychotherapy research has also demonstrated that some patients' need for a 'sense of control' is important to successful outcomes. Specifically, patients with a high need for control respond better when offered several treatment options whereas patients with a low need for control respond better to very specific direction on treatment. 22 Our overall point here is simple. We know that certain patient characteristics -and as importantly, how the health care provider responds to them -affect the success of therapeutic process and outcomes. Such findings would seem applicable to the pharmacological treatment of a sexual dysfunction that includes significant psychological and relationship factors.
In summary, no studies to date on combined medication/psychotherapy for PE have attended to all three elements: the type of intervention, the patientprovider relationship and patient characteristics. Yet attention to these latter aspects of the therapeutic process has the potential to greatly improve long-term adherence and overall treatment satisfaction.
Contributing to the development of emerging therapeutic paradigms Including psychological interventions as a part of pharmacological-based research is congruent with the current understanding of PE. That is, PE represents a psycho-physiological response accompanied by feelings and thoughts embedded in the contexts of a sexual relationship and of a level of physical health or disease in the male partner. With the growing popularity of medications to treat PE, Research on the efficacy of psychotherapy on premature ejaculation D Rowland et al the time is right for the development of new shortterm treatment models that combine medical and psychological treatment. As the medical community increasingly realizes, adequate treatment of a sexual problem often entails more than just fixing genital response. Rather, as for any condition involving psychological and relationship dimensions, treatment is a complex, relationship-embedded, technical process that requires attention to these multiple interacting factors. 23 We reiterate the point made by others: evidence-based practice for the treatment of such problems-PE or otherwise-is most comprehensive when it attends to all four dimensions of treatment: the specific treatment method, 24 the provider (whether physician or therapist: 25 ), the patient-provider relationship, 22 and the patient, inclusive of his relationship with his partner. 26 What is the relevance of these emerging therapeutic paradigms to the pharmaceutical interests? As pharmaceutical companies continue to research and develop new agents targeting quality of life conditions, psychological/behavioral factors will become increasingly important to demonstrating the success of the agent and ensuring treatment satisfaction (through patient defined end points). A preliminary though small body of research on PE seems to bear this out: in comparison with pharmacotherapy alone, combined treatment approaches appear to result in even more robust gains in ejaculatory latency in men with PE which, in turn, is likely to lead to increased treatment satisfaction and increased treatment adherence. 16 Understanding motivational factors that improve treatment compliance, particularly when such compliance involves a change in behavior and/or lifestyle, has broad implications that extend well beyond sexual health. Specifically, many chronic conditions involving biobehavioral interactions -including cardiovascular disease, cancer recovery, obesity, diabetes, arthritis, addictions, eating disorders, various emotional problems and so on -could be ameliorated by greater compliance with prescribed or recommended changes in behaviors and lifestyles. Thus, investment by pharmaceutical companies into research on combined treatment models that (using PE as a model) improve patient compliance could well yield positive health gains for much larger patient populations.
In summary, developing a combination treatment paradigm for PE supported by evidence-based research could contribute to the development of a seminal model for the treatment of other disorders that involve significant psychosocial and behavioral dimensions.
Providing a general 'goodwill' benefit to the pharmaceutical industry The final motivation for supporting research on psychotherapy efficacy focuses on the general benefits derived from this effort. Funding psychotherapeutic research could be cost effective in the long run. Pfizer, for example, spends between '$500 million dollars and takes 14 years to bring one new medicine from the lab to the patient.' Ninety percent are unsuccessful. 27 Yet, if only a fraction of the money it takes to fund one new drug were diverted to needed psychologically-based research, the resulting knowledge could yield significant gains in treatment outcomes and success for PE and other disorders that might be treated optimally through combination medical and psychological approaches.
Second, pharmaceutical research efforts will carry marketing cachet when they are perceived as broad endeavors that benefit not just the pharmaceutical company, but society as a whole. In the recent past, pharmaceutical companies have shown both the resolve and investment necessary to address major health and disease issues throughout the world; this, despite the negative impact such decisions typically have on bottom line profits. For example, the drug Mectizin was originally used for heartworm in dogs, but when discovered to be a possible antidote for river blindness, was subsequently developed and tested by Merck for human use. 28 Found primarily in West-African populations unable to afford the cost of treatment, river blindness is now being eradicated through free distribution of the drug to millions of people in some 31 developing countries. Other philanthropic initiatives, including those of GlaxoSmithKline, Lilly, Johnson & Johnson and Novartis, have been directed toward developing new drugs and vaccines for diseases that affect mostly poor countries with little potential to generate profit. 29 Furthermore, the formation of public-private partnerships in which pharmaceutical companies contribute pharmacological agents, patents and sometimes human capital to not-for-profit groups that provide coordination and management of product development represents another strategy marking pharmaceutical companies' commitment to take steps to control and eradicate disease, even when no or minimal direct economic incentive exists. 30 In summary, although perhaps less ambitious than the public health initiatives targeting disease in developing countries, we believe altruistic gestures of any kind -including those that benefit people here at home -and expansion of a responsible social agenda could reap significant long-term benefits for the corporation through increased consumer loyalty, particularly at a time when the image of the pharmaceutical industry as a whole appears to be suffering worldwide. As GlaxoSmithKline's mission statement proclaims, 'our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer'. 31 Such tag lines, supported by actual corporate practices made in the best interests of the public at large, recognize the business side of humanitarian efforts.
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Conclusion
In this article, we note and argue the following.
The efficacy of current psychotherapeutic treatments of PE is largely untested. The long-term success of pharmacological treatment of PE is likely to require combination medical and psychological approaches. To ensure positive long-term outcomes, evidencebased research documenting the potential effects of therapeutic content and process on PE is needed. Such information could assist in the development of efficacious combination treatment protocols for PE. Combination treatment models for PE could inform the treatment of other bio-behavioral medical disorders, including cardiovascular disease, obesity and diabetes. General support for endeavors that are perceived as beneficial to society as a whole will have image marketing value for pharmaceutical companies.
